Literature DB >> 25996428

Acute ocriplasmin retinopathy.

Mark W Johnson1, Abigail T Fahim, Rajesh C Rao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25996428      PMCID： PMC4457368          DOI： 10.1097/IAE.0000000000000667

Source DB:  PubMed          Journal:  Retina        ISSN： 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  27 in total

1.  Understanding the adverse effects of ocriplasmin - reply.

Authors:  Mark W Johnson; Abigail T Fahim
Journal:  JAMA Ophthalmol       Date:  2015-02       Impact factor: 7.389

2.  Understanding the adverse effects of ocriplasmin.

Authors:  David C Beebe
Journal:  JAMA Ophthalmol       Date:  2015-02       Impact factor: 7.389

3.  Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin.

Authors:  K B Freund; S A Shah; V P Shah
Journal:  Eye (Lond)       Date:  2013-05-03       Impact factor: 3.775

4.  Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin.

Authors:  David J Warrow; Michael M Lai; Auvni Patel; Joseph Raevis; Daniel M Berinstein
Journal:  Am J Ophthalmol       Date:  2014-09-16       Impact factor: 5.258

5.  Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion.

Authors:  Brian T Kim; Stephen G Schwartz; William E Smiddy; Rishi R Doshi; Jaclyn L Kovach; Audina M Berrocal; Andrew A Moshfeghi; Jorge A Fortun
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2013 Jul-Aug       Impact factor: 1.300

6.  Reversible vision loss and outer retinal abnormalities after intravitreal ocriplasmin injection.

Authors:  Aristomenis Thanos; Jonathan Hernandez-Siman; Kyle V Marra; Jorge G Arroyo
Journal:  Retin Cases Brief Rep       Date:  2014

7.  Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection.

Authors:  Abigail T Fahim; Naheed W Khan; Mark W Johnson
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389

8.  Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography.

Authors:  Michael D Tibbetts; Elias Reichel; Andre J Witkin
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389

9.  Ocriplasmin for treatment of stage 2 macular holes: early clinical results.

Authors:  John B Miller; Leo A Kim; David M Wu; Demetrios G Vavvas; Dean Eliott; Deeba Husain
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2014 Jul-Aug       Impact factor: 1.300

Review 10.  Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography.

Authors:  Yuji Itoh; Peter K Kaiser; Rishi P Singh; Sunil K Srivastava; Justis P Ehlers
Journal:  Ophthalmology       Date:  2014-09-07       Impact factor: 12.079
View more
  10 in total

1.  [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].

Authors:  M Maier; S Abraham; C Frank; C P Lohmann; N Feucht
Journal:  Ophthalmologe       Date:  2017-02       Impact factor: 1.059

2.  Predicting macular hole closure with ocriplasmin based on spectral domain optical coherence tomography.

Authors:  D H W Steel; C Parkes; V T Papastavrou; P J Avery; I A El-Ghrably; M S Habib; M T Sandinha; J Smith; K P Stannard; D Vaideanu-Collins; R J Hillier
Journal:  Eye (Lond)       Date:  2016-03-11       Impact factor: 3.775

Review 3.  Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.

Authors:  Irini Chatziralli; George Theodossiadis; Paraskevi Xanthopoulou; Michael Miligkos; Sobha Sivaprasad; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-30       Impact factor: 3.117

4.  A review of treatment for retinopathy of prematurity.

Authors:  Eric D Hansen; M Elizabeth Hartnett
Journal:  Expert Rev Ophthalmol       Date:  2019-03-29

Review 5.  The internal limiting membrane: Roles in retinal development and implications for emerging ocular therapies.

Authors:  Kevin Y Zhang; Thomas V Johnson
Journal:  Exp Eye Res       Date:  2021-03-20       Impact factor: 3.467

6.  Rhegmatogenous retinal detachment following intravitreal ocriplasmin.

Authors:  Haifa A Madi; Richard J Haynes; Diana Depla; Morten D de la Cour; Sarit Lesnik-Oberstein; Mahi M K Muqit; Niall Patton; Nick Price; David H W Steel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-08       Impact factor: 3.117

Review 7.  Ocriplasmin: who is the best candidate?

Authors:  Claudia M Prospero Ponce; William Stevenson; Rachel Gelman; Daniel R Agarwal; John B Christoforidis
Journal:  Clin Ophthalmol       Date:  2016-03-17

8.  EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG Substudy.

Authors:  David G Birch; Matthew S Benz; Daniel M Miller; Andrew N Antoszyk; Joseph Markoff; Petra Kozma; Esmeralda Meunier; Robert C Sergott
Journal:  Retina       Date:  2018-02       Impact factor: 4.256

9.  Reduced perfusion density of superficial retinal capillary plexus after intravitreal ocriplasmin injection for idiopathic vitreomacular traction.

Authors:  Lorenzo Iuliano; Giovanni Fogliato; Roberta Colombo; Riccardo Sacconi; Giuseppe Querques; Francesco Bandello; Marco Codenotti
Journal:  BMC Ophthalmol       Date:  2019-05-10       Impact factor: 2.209

10.  Enzymatic vitreolysis using reengineered Vibrio mimicus-derived collagenase.

Authors:  Mithun Santra; Maryada Sharma; Deeksha Katoch; Sahil Jain; Uma Nahar Saikia; Mangat R Dogra; Manni Luthra-Guptasarma
Journal:  Mol Vis       Date:  2021-04-01       Impact factor: 2.367
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.